Carna Biosciences, Inc. (4572) Stock Price

Karna Bioscience operates two main business segments: drug discovery and drug discovery support services. In its drug discovery business, the company conducts research and development of new drugs centered on kinase inhibitors and generates revenue by licensing them to pharmaceutical companies. Specifically, the company employs a business model that generates upfront payments, milestone payments, and royalty income.

In its drug discovery support business, the company provides products and services that support drug discovery research to pharmaceutical companies, biotech ventures, and research institutions such as universities. Specifically, the company offers kinase proteins and assay kits for sale, as well as profiling and screening services and cell-based assay services. Through these offerings, the company supports customers' drug discovery activities while generating funding for its own drug discovery research.

Through these business segments, Karna Bioscience aims to improve quality, reduce costs, and shorten timelines in kinase inhibitor research and development, thereby contributing to pharmaceutical companies' new drug creation. Additionally, the company uses funds generated from its drug discovery support business to accelerate the pace of its drug discovery research and development.

Carna Biosciences pursues a two-pillar growth strategy: drug discovery and drug discovery support services. In drug discovery, the company focuses on high unmet medical needs in oncology and immune/inflammatory diseases, aiming to develop innovative new drugs. The company prioritizes research and development of kinase inhibitors and generates revenue through licensing agreements with pharmaceutical companies.

The company's drug discovery support business assists pharmaceutical companies and research institutions through the provision of kinase-related products and services. By offering high-quality kinase protein products and profiling services, the company secures stable revenue streams. These earnings are reinvested in the drug discovery business to accelerate research and development progress.

Through these strategies, Carna Biosciences aims to maximize the value of its drug discovery pipeline and enhance corporate value. The company strengthens its revenue base through advancing clinical trials and establishing licensing agreements. Additionally, by expanding its drug discovery support business, the company secures stable cash flow and pursues sustainable growth.